查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015135

孤兒藥市場：2026-2032年全球市場預測（依治療領域、產品類型、給藥途徑、病患類型、支付者和分銷管道分類）

Orphan Drugs Market by Therapeutic Area, Product Type, Administration Route, Patient Type, Payer Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，孤兒藥市場價值將達到 1,815.6 億美元，到 2026 年將成長至 1,930.4 億美元，到 2032 年將達到 2,877.8 億美元，複合年成長率為 6.80%。

主要市場統計數據
基準年 2025 1815.6億美元
預計年份：2026年 1930.4億美元
預測年份 2032 2877.8億美元
複合年成長率 (%) 6.80%

簡要概述科學突破、監管獎勵和相關人員的期望如何重塑孤兒藥領域的策略。

孤兒藥領域已從一項小眾的科學研究發展成為一個策略性領域，創新、監管細則和相關人員的合作正在推動病患治療結果的變革性變化。分子生物學、精準診斷和監管獎勵的Start-Ups，正促使更廣泛的相關人員——從生物技術新創公司和學術聯盟到專科藥房和大型製藥公司——將孤兒藥計畫列為優先事項。這些趨勢，加上患者權益組織和支付方對臨床價值、安全性和長期效益的有力證據日益成長的期望，進一步加劇了這一領域的複雜性。因此，目前的生態系統需要涵蓋轉化科學、監管策略、價值驗證和價值鏈韌性的綜合能力。

本文著眼於技術成熟度、適應性法規結構以及不斷變化的支付方期望，這些因素正在從根本上改變孤兒藥的開發和商業化。

過去五年，罕見疾病治療的發現、開發和交付發生了翻天覆地的變化。基因編輯、病毒和非病毒載體工程以及生物製藥生產技術的成熟降低了技術門檻，使以往僅停留在理論階段的治療方法成為可能。同時，監管機構擴大了適應性框架、有條件核准和快速審查流程，以評估嚴格的早期證據，從而鼓勵製造商利用創新的數據策略更快地將療法推向市場。這些進展正在加速從單中心試驗轉向更嚴謹的多中心自然史研究和分散式試驗設計的轉變，在擴大患者可及性的同時，也產生了更高品質的證據。

對 2025 年關稅調整對孤兒藥治療在採購、生產韌性和商業合約方面的影響進行策略評估。

美國宣布將於2025年調整關稅政策，這將為孤兒藥的研發者和供應商帶來許多營運方面的考量，其累積影響遠不止於成本增加那麼簡單。關稅可能影響細胞和基因療法生產中使用的活性成分、生物製藥的原料、專用設備以及一次性耗材的採購。這些投入品進口關稅的提高可能會對企業的生產力造成壓力，迫使它們重新評估供應商關係、庫存策略和地理採購決策。實際上，企業可能會採取雙重採購策略或近岸外包來降低關稅波動帶來的風險，但這些調整將對前置作業時間、合格和監管產生影響。

將治療領域、治療方法複雜性、給藥途徑、分銷管道、患者人口統計特徵和支付方框架與業務策略聯繫起來的詳細細分見解。

深入的市場區隔揭示了科學、臨床和商業性的關注重點，以及營運複雜性最為顯著的領域。在分析治療路徑時，免疫學、感染疾病、神經病學和腫瘤學是推動孤兒藥研發的關鍵臨床領域。每個治療領域都有其獨特的臨床試驗設計、證據要求和患者招募挑戰。例如，腫瘤學和神經病學通常需要長期功能性終點，而代謝性疾病可能依賴基於生物標記的替代終點。這些差異決定了研發進度和證據策略。

比較區​​域趨勢，重點關注全球主要地區和市場的監管細微差別、支付方複雜性和商業化路徑。

區域趨勢以不同的方式影響發展重點、監管方式和商業化路徑。在美洲，監管流程較為成熟，核准核准和有條件核准的途徑也已相當完善。健全的創投和投資者生態系統也為創新治療方法的早期資金籌措提供了便利。這種環境促進了臨床創新，同時也提高了對全面安全監測和長期療效數據的期望。因此，在該地區運營的公司通常會優先考慮早期與支付方接洽和收集真實世界數據（RWE），以支援報銷談判。

分析決定哪些組織將孤兒藥創新轉化為患者可用治療方法的競爭角色、策略夥伴關係和營運專長。

孤兒藥領域的競爭動態呈現出生物技術創新者、成熟製藥公司、契約製造專家和臨床服務供應商並存的局面。領先的研發機構擁有雄厚的科學基礎、豐富的孤兒藥監管經驗，以及製定符合支付方要求的實證策略的能力。小規模、更靈活的生物技術公司往往透過探索基因編輯、非病毒遞送系統和新型生物結構等大膽的機制來推動治療方式的創新，而規模較大的公司則提供必要的規模和商業基礎設施，以確保患者能夠廣泛獲得治療。

為研發領導者提供可操作的、高優先級的行動方案，以協調孤兒藥治療中的臨床創新、支付方合作和供應韌性。

業界領導者應採取審慎且切實可行的措施，以成功應對複雜的科學問題、監管細則和支付方的嚴格審查。首先，將監管和衛生經濟學的專業知識融入早期研發計劃，使試驗設計、終點選擇和證據產生與支付方的預期保持一致。這種一致性可以減少後期返工，並增強獲得報銷的說服力。其次，制定具韌性的採購和生產策略，包括合格的替代供應商、戰略庫存緩衝和區域生產方案，以減輕地緣政治因素和關稅的干擾。

對用於從孤兒藥相關人員那裡獲得策略見解的定性研究和二手調查方法、專家訪談和證據三角檢驗進行透明的解釋。

本研究整合了第一手和第二手調查方法，旨在為策略決策建立可靠的證據基礎。第一手資料包括對臨床研究人員、監管顧問、支付方代表、生產專家和病患權益倡導組織領導人的深入訪談，從而提供關於營運挑戰、證據預期和准入趨勢的定性見解。第二手研究則納入了同行評審文獻、監管指導文件、臨床試驗註冊數據和上市公司資訊披露，以支持基於檢驗且最新資訊來源的觀察結果。對這些資料流檢驗，確保了結果的一致性，並突顯了專家意見與已發表報告有差異之處。

一項權威的綜合分析強調，需要製定統一的策略，將科學、製造和支付方之間的合作整合起來，以將創新轉化為永續的患者獲取途徑。

科學創新、監管合規和商業性可行性的整合，構成了現代罕見疾病治療惠及患者的路徑。從生物製藥和酵素療法到基因療法，治療方法的擴展既增加了機遇，也帶來了複雜性，因此，整合策略對於同時解決生產、證據產生和支付方參與等問題至關重要。成功的專案能夠預見監管預期，建構永續的生產供應鏈，並設計體現長期價值和風險共擔的支付模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：孤兒藥市場：依治療領域分類

  • 免疫學
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學

第9章：孤兒藥市場：依產品類型分類

  • 生物製藥
    • 酵素
    • 單株抗體
    • 重組蛋白
  • 基因治療
    • 非病毒載體
    • 病毒載體
  • 低分子
  • 組織療法

第10章：孤兒藥市場依給藥途徑分類

  • 吸入
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
  • 外用

第11章：以病患類型分類的孤兒藥市場

  • 成人版
  • 兒童

第12章：以支付方分類的孤兒藥市場

  • 政府項目
  • 自費
  • 私人保險

第13章：孤兒藥市場：依通路分類

  • 直接向患者銷售
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：孤兒藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：孤兒藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 孤兒藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國孤兒藥市場

第18章：中國孤兒藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-036C5CF3B4B9

The Orphan Drugs Market was valued at USD 181.56 billion in 2025 and is projected to grow to USD 193.04 billion in 2026, with a CAGR of 6.80%, reaching USD 287.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 181.56 billion
Estimated Year [2026] USD 193.04 billion
Forecast Year [2032] USD 287.78 billion
CAGR (%) 6.80%

A concise orientation to how scientific breakthroughs, regulatory incentives, and stakeholder expectations are reshaping strategy in the orphan drugs landscape

The orphan drugs domain has evolved from a niche scientific pursuit to a strategic arena where innovation, regulatory nuance, and stakeholder alignment determine transformative patient outcomes. Advances in molecular biology, precision diagnostics, and regulatory incentives have encouraged a broader set of stakeholders-biotech startups, academic consortia, specialty pharmacies, and larger pharmaceutical companies-to prioritize rare disease programs. These dynamics are compounded by rising expectations from patient advocacy groups and payers who demand robust evidence of clinical value, safety, and long-term benefits. Consequently, the ecosystem now requires integrated capabilities spanning translational science, regulatory strategy, value demonstration, and supply chain resilience.

Historically, orphan therapeutics emphasized single-gene disorders and small patient populations. Today, complexity has increased as drug developers pursue modalities such as gene therapies and biologics that necessitate different manufacturing, delivery, and post-market surveillance approaches. At the same time, the intersection of real-world evidence and adaptive regulatory pathways has created opportunities to shorten development timelines while preserving rigorous safety oversight. In this context, strategic decision-makers must balance scientific ambition with operational pragmatism, aligning clinical development plans with payer requirements and scalable commercialization models.

Looking ahead, the orphan drugs landscape will increasingly reward those organizations that can integrate deep scientific expertise with agile commercialization strategies. Cross-functional collaboration, early engagement with regulators and payers, and patient-centric program design will be central to converting scientific breakthroughs into sustainable therapies that meet unmet needs and operational realities.

An exploration of technological maturation, adaptive regulatory frameworks, and evolving payer expectations that are fundamentally altering orphan drugs development and commercialization

The last five years have seen transformative shifts that have recalibrated how orphan therapeutics are discovered, developed, and delivered. Technological maturation in gene editing, viral and non-viral vector engineering, and biologic manufacturing has lowered technical barriers and enabled therapeutic approaches that were previously theoretical. Concurrently, regulatory agencies have expanded adaptive frameworks, conditional approvals, and accelerated review pathways that reward rigorous early evidence, thereby encouraging manufacturers to bring therapies forward with novel data strategies. These developments have promoted a move away from one-off, single-center trials toward more robust, multicenter natural history studies and decentralized trial designs that increase patient access while generating higher-quality evidence.

Commercially, the pricing and reimbursement conversation has matured. Payers now expect integrated evidence packages that include long-term follow-up, health economic modeling, and post-market risk-sharing arrangements. As a result, commercial teams have had to adopt earlier and more sophisticated engagement with payers to negotiate value-based contracts and outcomes-based arrangements. Simultaneously, manufacturing innovations-such as modular facilities and contract development and manufacturing organizations that specialize in cell and gene therapies-have altered capital planning and partnerships, enabling smaller companies to scale without the full burden of building in-house capacity.

Moreover, patient advocacy and digital health platforms have become invaluable partners for recruitment, natural history data capture, and long-term monitoring. These shifts collectively emphasize that success in the orphan drugs arena is no longer only about scientific differentiation; it depends equally on regulatory foresight, innovative commercial models, and collaborative supply chain design.

A strategic assessment of how tariff adjustments influence procurement, manufacturing resilience, and commercial contracting for orphan therapeutics in 2025

Changes in United States tariff policy announced for 2025 introduce several operational considerations for orphan drug developers and suppliers, with cumulative impacts that extend beyond simple cost increases. Tariffs can affect the sourcing of active pharmaceutical ingredients, biologic raw materials, specialized equipment, and single-use consumables used in cell and gene therapy manufacturing. When such inputs face higher import duties, organizations encounter pressure on production economics, which can lead to re-evaluation of supplier relationships, inventory strategies, and geographic sourcing decisions. In practice, companies may pursue dual-sourcing strategies or nearshoring to mitigate exposure to tariff-related volatility, but these adjustments carry lead-time, qualification, and regulatory implications.

In addition, tariff-driven cost shifts have implications for contract negotiations with payers and providers. Manufacturers may need to build more robust cost transparency into pricing discussions and to explore alternative commercial models that distribute risk across stakeholders, such as annuity payments or outcomes-based contracts. Moreover, tariffs can exacerbate supply chain fragility for therapies that rely on tightly controlled cold chains or single-source components. Consequently, supply continuity planning must be elevated to a strategic priority, with increased investments in redundancy, buffer inventory, and supplier qualification to ensure uninterrupted patient access.

Finally, the macroeconomic and policy signaling associated with tariff changes can influence investment decisions. Investors and strategic partners will closely assess how tariff exposures affect unit costs, gross margins, and long-term scalability. For companies operating in global clinical development, tariff dynamics may also prompt discussions about where to site manufacturing or clinical supply chains to optimize both regulatory alignment and cost efficiency. In sum, the cumulative impact of tariff adjustments in 2025 will be felt across procurement, manufacturing, commercial contracting, and capital allocation decisions.

In-depth segmentation insights linking therapeutic focus, modality complexity, administration routes, distribution channels, patient demographics, and payer frameworks to operational strategy

Insightful segmentation reveals where scientific, clinical, and commercial focus is concentrated and where operational complexity is most acute. When analyzing therapeutic pathways, attention centers on immunology, infectious diseases, metabolic disorders, neurology, and oncology as the primary clinical domains driving orphan drug activity. Each therapeutic area presents distinct clinical trial designs, evidence requirements, and patient recruitment challenges; oncology and neurology, for example, often necessitate long-term functional endpoints, whereas metabolic disorders may rely on biomarker-driven surrogate endpoints. These differences dictate development timelines and evidence strategies.

Product modality also defines development, manufacturing, and delivery constraints. Biologics, gene therapies, small-molecule drugs, and tissue therapies occupy separate development pathways; within biologics, enzymes, monoclonal antibodies, and recombinant proteins each require tailored production platforms and cold-chain logistics, while gene therapy development splits between non-viral and viral vector strategies with differing vector design, manufacturing complexity, and regulatory scrutiny. Administration route further shapes clinical operations and patient adherence considerations; inhalation, injectable, oral, and topical routes each impose distinct formulation and distribution needs, and injectable approaches-intramuscular, intravenous, or subcutaneous-carry specific clinical site requirements and monitoring protocols that affect both trial conduct and commercial delivery.

Distribution dynamics encompass direct-to-patient, hospital pharmacy, online pharmacy, and retail pharmacy channels, and these pathways interact with patient demographics and payer frameworks. Patient type segmentation into adult and pediatric populations introduces ethical, dosing, and trial design nuances that influence enrollment and regulatory strategy. Finally, payer types-government programs, out-of-pocket payers, and private insurance-determine coverage pathways, reimbursement negotiations, and the degree of evidence needed to secure access. Together, these segmentation lenses create a multidimensional view that informs operational planning, stakeholder engagement, and commercialization sequencing.

Comparative regional dynamics emphasizing regulatory nuance, payer complexity, and commercialization pathways across major global regions and markets

Regional dynamics shape development priorities, regulatory approaches, and commercialization pathways in distinct ways. In the Americas, regulatory pathways have matured to support accelerated approvals and conditional pathways, and a robust venture and investor ecosystem fosters early-stage financing for novel modalities. This environment encourages clinical innovation but also raises expectations for comprehensive safety monitoring and long-term outcome data. Consequently, companies operating in this region often prioritize early payer engagement and real-world evidence collection to support reimbursement discussions.

Europe, Middle East & Africa presents a diverse regulatory and market-access landscape where centralized and national authorities coexist, creating variable reimbursement outcomes across jurisdictions. Adaptive pathways and conditional authorizations coexist with rigorous health technology assessment processes that emphasize comparative effectiveness and budget impact. Therefore, strategies in this region require well-orchestrated HTA dossiers, engagement with national payer authorities, and localized access plans that reflect heterogeneous pricing and reimbursement frameworks.

Asia-Pacific markets display rapid adoption of innovative therapies alongside variable regulatory and reimbursement maturity. Several markets in this region are accelerating pathways for regenerative medicines and gene therapies and are increasingly investing in local manufacturing capabilities to build supply security. However, heterogeneity remains across the region in payer coverage and patient affordability. As a result, companies often pursue tiered market entry strategies that balance early access programs, local partnerships, and capacity-building to achieve sustainable commercialization while addressing regional expectations for affordability and capacity.

An analysis of competitive roles, strategic partnerships, and operational specialization that determine which organizations convert orphan drug innovation into accessible therapies

Competitive dynamics in the orphan drugs arena reflect a mix of specialized biotechnology innovators, established pharmaceutical companies, contract manufacturing specialists, and clinical service providers. Leading development organizations combine deep scientific platforms with experience in navigating orphan regulatory pathways and designing evidence strategies that meet payers' requirements. Smaller, nimble biotech firms often drive modality innovation, pursuing bold mechanisms such as gene editing, non-viral delivery systems, and novel biologic constructs, while larger firms bring the scale and commercial infrastructure required for broad patient access.

Contract development and manufacturing organizations have become strategic partners, not merely vendors, because their capabilities in viral vector production, aseptic fill-finish, and quality systems are critical for time-sensitive programs. Similarly, specialty pharmacies and hub services play an increasing role in patient onboarding, home administration logistics, and outcomes data collection, effectively extending manufacturers' capacity to maintain adherence and monitor long-term safety. Furthermore, diagnostic companies and clinical data platforms serve as enablers by supplying companion diagnostics and natural history datasets that underpin targeted development strategies.

Across the competitive landscape, collaborations and licensing arrangements are common. Strategic partnerships that align scientific assets with manufacturing scale or payer-oriented commercialization expertise tend to accelerate development pathways and reduce execution risk. Consequently, corporate strategies now prioritize flexible alliance models, intellectual property clarity, and shared-risk commercial agreements that align incentives across the value chain.

Practical and prioritized actions for development leaders to align clinical innovation, payer engagement, and supply resilience for orphan therapeutics

Industry leaders should adopt a set of deliberate, actionable moves to navigate scientific complexity, regulatory nuance, and payer scrutiny successfully. First, integrate regulatory and health economics expertise into early development planning to align trial design, endpoint selection, and evidence generation with payer expectations; this alignment will reduce late-stage rework and strengthen reimbursement narratives. Second, develop resilient sourcing and manufacturing strategies that include qualified secondary suppliers, strategic inventory buffers, and options for regional manufacturing to mitigate geopolitical and tariff-related disruption.

Third, institutionalize patient engagement and real-world evidence collection as core programmatic activities rather than ancillary tasks. Patient registries, remote monitoring, and structured long-term follow-up should be embedded in both clinical development and post-market phases to demonstrate sustained value. Fourth, pursue flexible commercial contracting models that accommodate payers' demand for value demonstration; these may include outcomes-based agreements, staged payments, or shared-risk arrangements that distribute financial exposure while aligning incentives for patient outcomes. Fifth, invest in partnerships with specialized contract manufacturers, diagnostics vendors, and specialty pharmacies to leverage external capabilities while preserving strategic control over clinical data and commercialization levers.

Finally, empower cross-functional governance that brings clinical, regulatory, commercial, and manufacturing leaders into early and continuous dialogue. This approach shortens decision cycles, improves risk identification, and increases the likelihood that scientific breakthroughs translate into therapies that are safe, accessible, and financially sustainable within the healthcare system.

A transparent description of qualitative and secondary research approaches, expert interviews, and evidence triangulation used to derive strategic insights for orphan drug stakeholders

This research synthesizes primary and secondary methodologies to build a robust evidence base that informs strategic decision-making. Primary inputs include in-depth interviews with clinical investigators, regulatory advisors, payer representatives, manufacturing specialists, and patient advocacy leaders, providing qualitative insights on operational challenges, evidence expectations, and access dynamics. Secondary research incorporates peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to ground observations in verifiable, up-to-date sources. These data streams are triangulated to ensure consistency and to highlight areas where expert opinion diverges from public reports.

Analytical methods emphasize thematic synthesis and scenario analysis rather than quantitative forecasting. The study applies comparative case review to identify repeatable patterns in regulatory strategy, commercialization approaches, and manufacturing scale-up. Risk assessment frameworks were used to evaluate supply chain vulnerabilities and tariff exposure, while health economics experts reviewed typical evidence packages and reimbursement negotiation levers used in orphan programs. Quality assurance included cross-validation of interview findings against public filings and regulatory guidance, and a structured peer review by subject matter experts to reduce interpretive bias.

Ethical considerations were observed in all primary engagements, with interview participants providing informed consent and proprietary information treated under confidentiality agreements where appropriate. The methodology prioritizes transparency in source attribution and methodological limitations, offering readers clarity on where qualitative judgment informed conclusions and where empirical regulatory or scientific sources underpin recommendations.

A conclusive synthesis emphasizing the need for integrated scientific, manufacturing, and payer-aligned strategies to convert innovation into sustained patient access

Bringing together scientific innovation, regulatory navigation, and commercial pragmatism defines the modern pathway for orphan therapeutics to reach patients. The expansion of modalities-from biologics and enzyme therapies to gene therapy constructs-has multiplied both opportunity and complexity, necessitating integrated strategies that address manufacturing, evidence generation, and payer engagement concurrently. Successful programs are those that anticipate regulatory expectations, build durable manufacturing supply chains, and design payment models that reflect long-term value and shared risk.

As the healthcare environment becomes more interconnected, patient advocacy groups and real-world data platforms will increasingly shape clinical design and access outcomes. In parallel, geopolitical and policy shifts-such as tariff changes-underscore the need for flexible sourcing and regional manufacturing strategies to protect continuity of supply. These dynamics mean that organizations that combine scientific excellence with operational resilience and value-focused commercialization will be best positioned to deliver sustainable patient impact. Ultimately, the orphan drugs sector rewards those who balance ambition with disciplined execution, turning breakthrough science into therapies that patients can access reliably and affordably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Orphan Drugs Market, by Therapeutic Area

  • 8.1. Immunology
  • 8.2. Infectious Diseases
  • 8.3. Metabolic Disorders
  • 8.4. Neurology
  • 8.5. Oncology

9. Orphan Drugs Market, by Product Type

  • 9.1. Biologics
    • 9.1.1. Enzymes
    • 9.1.2. Monoclonal Antibodies
    • 9.1.3. Recombinant Proteins
  • 9.2. Gene Therapy
    • 9.2.1. Non-Viral Vector
    • 9.2.2. Viral Vector
  • 9.3. Small-Molecule
  • 9.4. Tissue Therapy

10. Orphan Drugs Market, by Administration Route

  • 10.1. Inhalation
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
  • 10.4. Topical

11. Orphan Drugs Market, by Patient Type

  • 11.1. Adult
  • 11.2. Pediatric

12. Orphan Drugs Market, by Payer Type

  • 12.1. Government Programs
  • 12.2. Out-Of-Pocket
  • 12.3. Private Insurance

13. Orphan Drugs Market, by Distribution Channel

  • 13.1. Direct-To-Patient
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy

14. Orphan Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Orphan Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Orphan Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Orphan Drugs Market

18. China Orphan Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. BioMarin Pharmaceutical Inc.
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Novartis AG
  • 19.15. Novo Nordisk A/S
  • 19.16. Pfizer Inc.
  • 19.17. Sanofi S.A.
  • 19.18. Takeda Pharmaceutical Company Limited
  • 19.19. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ORPHAN DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)